| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Safety primary endpoint achievedMedian treatment duration of 4 months with a range of 2 to 12 months and three patients remain ...
 
																	TransCode Therapeutics Inc. (NASDAQ: RNAZ) to acquire Polynoma LLC and receive $25 million investment from CK Life Sciences.
 
																	BOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Comp...
 
																	
 
																	
 
																	
 
																	
 
																	
